Related Experiment Video
Updated: May 20, 2026
07:39
Induction of Acute Skeletal Muscle Regeneration by Cardiotoxin Injection
Published on: January 1, 2017
Cardiotoxin-I: an unexpectedly potent insulinotropic agent
Thi Tuyet Nhung Nguyen1, Benjamin Folch, Myriam Létourneau
1INRS-Institut Armand-Frappier, Université du Québec, 531 Boulevard des Prairies, Ville de Laval, Québec H7V 1B7, Canada.
Chembiochem : a European Journal of Chemical Biology
|July 19, 2012
Summary
Researchers discovered cardiotoxin-I (CTX-I) from Naja kaouthia snake venom stimulates insulin secretion from pancreatic beta cells. This novel insulinotropic toxin functions independently of glucose, offering new research and therapeutic possibilities.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Insulin secretion by pancreatic beta cells is a complex physiological process.
- Glucose is a primary regulator of insulin release, but other factors are involved.
- Understanding beta cell physiology is key to identifying new therapeutic targets for metabolic diseases.
Purpose of the Study:
- To investigate Naja kaouthia snake venom for insulinotropic metabolites.
- To characterize the effects of identified venom components on insulin secretion.
- To assess the potential of novel compounds for studying beta cell function.
Main Methods:
- Fractionation of Naja kaouthia snake venom.
- Assessment of insulin secretion from INS-1E cells using MTT and LDH assays.
- Evaluation of cardiotoxin-I (CTX-I) effects on insulin release with and without glucose.
- Testing CTX-I for hemolytic and vasoconstrictive activities.
Main Results:
- Cardiotoxin-I (CTX-I) was identified as a potent inducer of insulin secretion from INS-1E cells.
- CTX-I stimulated insulin secretion without compromising cell viability or integrity.
- Insulin release was observed even in the absence of glucose, indicating a glucose-independent mechanism.
- CTX-I exhibited minimal hemolytic and vasoconstrictive effects, differing from typical cardiotoxins.
Conclusions:
- Cardiotoxin-I from Naja kaouthia venom is a novel insulinotropic agent.
- CTX-I provides a new tool for investigating pancreatic beta cell physiology.
- This finding may open new therapeutic avenues for diabetes and related metabolic disorders.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...